

INNOVATION IN UROTHELIAL CANCER 2025

“Personalization, Tumor Biology
and New Therapeutic Frontiers”

11 December 2025
16:00 – 18:30 (CET)

**Hospital Universitario
HM Sanchinarro**
Auditorio Reina Sofía
C/ de Oña,10, 28050 Madrid

Organiza	Director del curso
	Dra. Elena Sevillano Fernández M.D. PhD Unidad de Tumores Urológicos, Ginecológicos y piel HM Hospitales
	Coordinador del curso
	Dr. Jesús García-Donas M.D PhD M.D. Unidad de Tumores Urológicos, Ginecológicos y piel




hm hospitales

SCIENTIFIC AGENDA

Speakers:

Dr. Joaquim Bellmunt Dr. Pablo Gajate
Dr. Guillermo de Velasco Dr. Alfonso Gómez de Liaño
Dr. Félix Guerrero

Course Directors and Moderators:

Dra. Elena Sevillano
Dr. Jesús García-Donas

16:00 – 16:10 | Welcome and Introduction

SESSION I – EARLY-STAGE DISEASE

16:10 – 16:30 | NMIBC in Transformation: Is it Time to Integrate Immunotherapy?

- Redefining BCG unresponsiveness
- Practical considerations of long-term subcutaneous immunotherapy
- How should we define BCG failure in 2025?
- What is the role of the multidisciplinary team?

SESSION II – MIBC & BLADDER-SPARING STRATEGIES

16:30 – 17:30 | Muscle-Invasive Disease: Response- and ctDNA-Guided Personalization

- Insights from neoadjuvant trials: can we avoid cystectomy?
- ctDNA vs pCR as prognostic tools
- Defining cCR and optimizing bladder preservation
- Can ctDNA clearance guide treatment de-escalation?

SESSION III – ADVANCED DISEASE & PRECISION MEDICINE

17:30 – 18:15 | What’s Next in Metastatic Urothelial Cancer?

- Front-line strategies:
- Sequencing ADCs and IO: how to choose wisely
- Genomic biomarkers: FGFR, HER2
- Emerging role of artificial intelligence in diagnosis and prediction
- Are we ready for a platinum-free future?
- How can we better integrate genomic profiling into real-world practice?

CLOSING DISCUSSION

18:15 – 18:30 | Open Q&A and Final Remarks

- What should change in our clinical practice after tomorrow?
- What research questions remain unanswered?

Patrocinan




hm hospitales
Somos tu Salud